First report of the genetic background of Marfan syndrome in Polish patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 11, 2013, Pages 646-648

  Wypasek, Ewa ^a,b   Potaczek, Daniel P ^a,c   Sta̧por, Renata ^a   Coucke, Paul J ^d   De Backer, Julie ^d   De Paepe, Anne M ^d   Undas, Anetta ^a,b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AORTA ANEURYSM; CASE REPORT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; LETTER; MALE; MARFAN SYNDROME; MITRAL VALVE REGURGITATION; PHENOTYPE; POLAND; SCOLIOSIS; YOUNG ADULT; CHILD; GENETICS; PEDIGREE;

ADULT; CHILD; FEMALE; HUMANS; MALE; MARFAN SYNDROME; PEDIGREE; POLAND; YOUNG ADULT;

EID: 84891877806     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1986     Document Type: Letter

References (12)

1. Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007; 3: 252-258.
2. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996; 4: 417-426.
3. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 7: 476-485.
4. Dietz HC, Pyeritz RE, Hall BD, et al. The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics. 1991; 2: 355-361.
5. Dietz HC. 2006 Curt Stern Award Address. Marfan syndrome: from molecules to medicines. Am J Hum Genet. 2007; 4: 662-667.
6. De Backer J, Loeys B, Leroy B, et al. Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome. Clin Genet. 2007; 3: 188-198.
7. Hung CC, Lin SY, Lee CN, et al. Mutation spectrum of the fibrillin-1 (FBN1) gene in Taiwanese patients with Marfan syndrome. Ann Hum Genet. 2009; 6: 559-567.
8. Judge DP, Biery NJ, Keene DR, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004; 2: 172-181.
9. Eldadah ZA, Brenn T, Furthmayr H, Dietz HC. Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J Clin Invest. 1995; 2: 874-880.
10. Schrijver I, Liu W, Odom R, et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet. 2002; 2: 223-237.
11. Charbonneau NL, Carlson EJ, Tufa S, et al. In vivo studies of mutant fibrillin-1 microfibrils. J Biol Chem. 2010; 32: 24943-24955.
12. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003; 4: 2750-2757.